Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 8, 2010, Pages 946-951

  El Shabrawi, Mortada Hassan ^a   Mohsen, Nabil A ^a   Sherif, Mai M ^a   El Karaksy, Hanaa M ^a   Abou Yosef, Hazem ^a   El Sayed, Hussein M ^a   Riad, Hany ^a   Bahaa, Nevine ^a   Isa, Mona ^a   El Hennawy, Ahmed ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

ActiTest; FibroTest; hepatitis C in children; noninvasive diagnosis of hepatitis C virus

Indexed keywords

BIOCHEMICAL MARKER; BIOLOGICAL MARKER;

ACTITEST; ADULT; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; DISEASE ACTIVITY; FEMALE; FIBROTEST; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER EXAMINATION; LIVER FIBROSIS; MALE; NON INVASIVE PROCEDURE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; VALIDATION PROCESS; ADOLESCENT; BLOOD; BLOOD ANALYSIS; COMPLICATION; EGYPT; LIVER CIRRHOSIS; PATHOLOGY; PROCEDURES; VALIDATION STUDY; VIROLOGY;

ADOLESCENT; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; CHILD; CHILD, PRESCHOOL; EGYPT; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; PROSPECTIVE STUDIES;

EID: 77955215231     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328336ec84     Document Type: Article

References (31)

1. Paik SW. Goals of treatment, indication, and treatment for chronic hepatitis C. Korean J Gastroenterol 2008; 51:368-371.
2. El-Hawary MA, El-Raziky MS, Esmat G, Soliman H, Abouzied A, El-Raziky M, et al. Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt. World J Gastroenterol 2007; 13:2846-2851.
3. Medhat A, Shehata M, Magder LS, Mikhail N, Abdel-Baki L, Nafeh M, et al. Hepatitis c in a community in upper Egypt: risk factors for infection. Am J Trop Med Hyg 2002; 66:633-638.
4. Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel-Hamid M, Gamil F, et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology 2001; 33:248-253.
5. Goodman ZD, Makhlouf HR, Liu L, BalistreriW, Gonzalez-Peralta RP, Haber B, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008; 48:691-692. (Author reply 692).
6. Halfon P, Munteanu M, Poynard T. Fibrotest-Actitest as a non invasive marker of liver fibrosis seven years ago: a 2008 updated meta-analyses of FT diagnostic and prognostic values in chronic liver diseases. Gastroenterol Clin Biol 2008; 32:22-39.
7. Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, et al. Biomarkers of liver fibrosis. Adv Clin Chem 2008; 46:131-160.
8. Bosch J. Towards the non-invasive diagnosis of cirrhosis: the nuts-cirrhosis connection. J Hepatol 2009; 50:4-6.
9. Poynard T, Muntenau M, Morra R, Ngo Y, Imbert-Bismut F, Thabut D, et al. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Gastroenterol Clin Biol 2008; 32 (6 Suppl 1): 8-21.
10. Dolmazashvili E, Zhamutashvili M, Svanidze M, Nizharadze N, Abutidze A. Fibroscan and fibrotest/fibromax to assess liver fibrosis/cirrhosis in patients with chronic HBV and HCV infection in Georgia. Georgian Med News 2008; 165:83-87.
11. Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. J Viral Hepat 2009; 16:203-213.
12. Ngo Y, Yves Benhamou, Thibault V, Ingiliz P, Muntenau M, Lebray P, et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS ONE 2008; 3:e2573.
13. Naveau S, Gaudé G, Asnacios A, Agostini H, Abella A, Barri-Ova N, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49:97-105.
14. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al. The LIDO Study Group and the CYTOL Study Group: diagnostic value of biochemical markers (FibroTest FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6:6.
15. Jacqueminet S, Lebray P, Morra R, Munteanu M, Devers L, Messous D, et al. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. Clin Gastroenterol Hepatol 2008; 6:828-831.
16. Poynard T, Morra R, Halfon P, Casté ra L, Ratziu V, Imbert-Bismut F, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7:40.
17. Hermeziu B, Messous D, Fabre M, Munteanu M, Baussan C, Bernard O, et al. Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. Gastroenterol Clin Biol 2009 [Epub ahead of print]
18. Rubio A, Monpoux F, Huguon E, Truchi R, Triolo V, Rosenthal-Allieri MA, et al. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children. J Pediatr Gastroenterol Nutr 2009; 49:599-606.
19. De Ledinghen V, Le Bail B, Rebouissoux L, Fournier C, Foucher J, Miette V, et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with FibroTest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr 2007; 45:443-450.
20. Rothman KJ. Declaration of Helsinki should be strengthened. BMJ 2000; 321:442-445.
21. Imbert-Bismut F, Ratziu V, Laurence Pieroni L, Charlotte F, Benhamou Y, Poynard T, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075.
22. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50:1344-1355.
23. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
24. Fontanges T, Bailly F, Trepo E, Chevallier M, Maynard-Muet M, Nalet B, et al. Discordance between biochemical markers of liver activity and fibrosis Actitest(R)-Fibrotest(R) and liver biopsy in patients with chronic hepatitis C. Gastroenterol Clin Biol 2008; 32:858-865.
25. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36:S47-S56.
26. Poynard T, Ratziu V, Benmanov Y, Di Martino V, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 2000; 20:47-55.
27. Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem A 2006; 52:1887-1896.
28. Thabut D, Trabut JB, Massard J, Rudler M, Muntenau M, Messous D, Poynard T. Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study. Liver Int 2006; 26:271-278.
29. Thabut D, Imbert-Bismut F, Cazals-Hatem D, Messous D, Muntenau M, Valla DC, et al. Relationship between the FibroTest and portal hypertension in patients with liver disease. Aliment Pharmacol Ther 2007; 26:359-368.
30. Narkewicz MR, Cabrera R, Gonzá lez-Peralta RP. The C of viral hepatitis in children. Semin Liver Dis 2007; 27:295-311.
31. Mohan P, Colvin C, Glymph C, Chandra R, Kleiner D, Patel K, et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr 2007; 150:168-174.e1.